Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 15/20 | 0.45 |
| ▸ | CTRC | Q99895 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894751 | 1.00 | CMA1 (0.45) | CMA1CTRCHDAC8KCNH2ELANE | |
| SCHEMBL10224239 | 0.92 | CMA1 (0.49) | CMA1CTRCHDAC8KCNH2ELANE | |
| SCHEMBL20952290 | 0.90 | CMA1 (0.49) | CMA1CTRCHDAC8KCNH2ELANE | |
| SCHEMBL474974 | 0.90 | CMA1 (0.49) | CMA1CTRCHDAC8KCNH2ELANE | |
| SCHEMBL895419 | 0.86 | CMA1 (0.47) | CMA1CTRCKCNH2ELANE | |
| SCHEMBL22344929 | 0.86 | CMA1 (0.47) | CMA1CTRCKCNH2ELANE | |
| SCHEMBL16309212 | 0.85 | KCNH2 (0.52) | CMA1CTRCKCNH2ELANE | |
| SCHEMBL896123 | 0.84 | KCNH2 (0.56) | CMA1CTRCKCNH2ELANE | |
| SCHEMBL10224155 | 0.83 | KCNH2 (0.63) | CMA1CTRCKCNH2ELANE | |
| SCHEMBL10222777 | 0.83 | KCNH2 (0.46) | CMA1CTRCKCNH2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | claimed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | CMA1 920/4885CTRC 239/4885HDAC8 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.